Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. With Humira revenue degrading, it would be wise to wait for evidence of a revenue replacement before ...

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...

Sees FY24 U.S Humira sales $7.4B, down $400M from prior view. Published first on TheFly – the ultimate source for real-time, ...

AbbVie (ABBV) stock hits all-time high after beating Q3 earnings expectations with newer immunology drugs outperforming ...

While Humira's sales volumes have increasingly shifted to other drugs over successive quarters this year, that has also ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

AbbVie Inc (ABBV) reports robust sales growth driven by Skyrizi and Rinvoq, raises full-year guidance, and announces a 5.8% ...